Homogenous Mobility Shift Assay (HMSA) Overcomes the Limitations of ELISA and ECLIA Assays for Monitoring Infliximab (IFX), Adalimumab (ADA), and Associated Anti-drug Antibodies in Serum

被引：4
|
作者：
Egea-Pujol, Laia [1 ]
Reddy, Rukmini [1 ]
Patel, Shruti [1 ]
Christie, Raymond [1 ]
Salbato, Jared [1 ]
Shah, Shawn [1 ]
Hauenstein, Scott [1 ]
Singh, Sharat [1 ]
机构：
[1] Prometheus Therapeut & Diagnost, Res, San Diego, CA USA
来源：
AMERICAN JOURNAL OF GASTROENTEROLOGY | 2013年 / 108卷
关键词：
D O I：
10.14309/00000434-201310001-01817
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1817
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 12 条
  • [1] Analysis of Anti-drug Antibodies (ADA) to Adalimumab in Patient Serum Using a Novel Homogeneous Mobility Shift Assay
    Wang, Shui Long
    Ohrmund, Linda
    Ling, Nicholas
    Singh, Sharat
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2010, 105 : S444 - S445
  • [2] Evaluation of the Homogenous Mobility Shift Assay for Infliximab and Adalimumab Anti-drug Antibody Detection in the Clinical Laboratory
    Keating, Paula Elizabeth
    Hock, Barry D.
    Chin, Paul K. L.
    O'Donnell, John Liston
    Barclay, Murray Lindsay
    [J]. THERAPEUTIC DRUG MONITORING, 2024, 46 (05) : 619 - 626
  • [3] PROACTIVE MONITORING OF INFLIXIMAB (IFX) AND ADALIMUMAB (ADA) DRUG AND ANTI-DRUG ANTIBODY CONCENTRATION UTILIZING THE LABCORP ASSAY IN INFLAMMATORY BOWEL DISEASE (IBD) PATIENTS
    Perinbasekar, Rajiv A.
    Brown, Sara A.
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond K.
    [J]. GASTROENTEROLOGY, 2017, 152 (05) : S392 - S392
  • [4] Subtyping anti-infliximab antibodies by the homogenous mobility shift assay (HMSA): potential utility in a pharmacokinetic case study
    Chow, Ke Li
    Keating, Paula Elizabeth
    O'Donnell, John Liston
    [J]. PATHOLOGY, 2023, 55 (04) : 587 - 590
  • [5] ANTI-DRUG ANTIBODIES (ADA): ASSAY PERFORMANCE IN PATIENTS TREATED FOR INFLAMMATORY BOWEL AND RHEUMATIC DISEASE WITH BIODRUGS, ADALIMUMAB AND INFLIXIMAB
    O'Donnell, J.
    Liu, J.
    Keating, P.
    Hock, B.
    Spellerberg, M.
    Barclay, M.
    Stamp, L.
    [J]. INTERNAL MEDICINE JOURNAL, 2017, 47 : 15 - 15
  • [6] Clinical Utility of Measuring Infliximab (IFX) and Adalimumab (ADA) and Anti-drug Antibody Levels Using the LabCorp Assay in Patients With Inflammatory Bowel Disease (IBD)
    Brown, Sara
    Perinbasekar, Rajiv
    Syed, Nauroz
    Lonsako, Shumet
    Cross, Raymond
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2017, 112 : S406 - S406
  • [7] Therapeutic Drug Monitoring of Infliximab and Adalimumab through Concentration and Anti-Drug Antibodies Assessment; Comparison of Sanquin Diagnostics and Theradiag Assays
    Vroemen, Wim H. M.
    Agata, Shakira S.
    van Beers, Joyce J. B. C.
    Damoiseaux, Jan G. M. C.
    [J]. ANTIBODIES, 2024, 13 (03)
  • [8] Positivity thresholds of total infliximab and adalimumab anti-drug antibody assay: The prevalence of clearing and transient anti-drug antibodies in a national therapeutic drug monitoring service
    Nice, R.
    Chanchlani, N.
    Green, H.
    Bewshea, C.
    Kennedy, N.
    Ahmad, T.
    Goodhand, J.
    McDonald, T.
    Perry, M.
    [J]. JOURNAL OF CROHNS & COLITIS, 2020, 14 : S018 - S019
  • [9] Discrimination of Anti-drug Antibodies With Neutralizing Capacity in Infliximab-and Adalimumab-Treated Patients: Comparison of the Homogeneous Mobility Shift Assay and the Affinity Capture and Elution Assay
    Hock, Barry D.
    McKenzie, Judith L.
    Goddard, Liping
    Smith, Stewart M.
    McEntyre, Christopher J.
    Keating, Paula E.
    [J]. THERAPEUTIC DRUG MONITORING, 2018, 40 (06) : 705 - 715
  • [10] Comparison of Homogeneous Mobility Shift Assay and Solid Phase ELISA for the Measurement of Drug and Anti-Drug Antibody (ADA) Levels in Serum From Patients Treated With Anti-TNF Biologics
    Hauenstein, Scott
    Ohrmund, Linda
    Salbato, Jared
    Reddy, Rukmini
    McCowen, Kevin
    Monk, Patrick
    Lockton, Steven
    Wang, Shui-Long
    Singh, Sharat
    [J]. GASTROENTEROLOGY, 2012, 142 (05) : S538 - S538
12